What is the 13F Pro Quality Score for BDSX?

13F Pro ranks BIODESIX INC (BDSX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BDSX's current score at https://13fpro.ai/research/BDSX (free sign-up required for the full ranking).

Which hedge funds own the most BDSX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BDSX include AIGH Capital Management, Telemark Asset Management,, abrdn plc. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BDSX as soon as new 13F filings post.

Where does 13F Pro source BDSX data?

All BIODESIX INC fundamentals and ownership data come directly from SEC EDGAR. BIODESIX INC files with the SEC under CIK 1439725. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BDSX in?

BIODESIX INC (BDSX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BDSX research updated on 13F Pro?

BDSX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIODESIX INC(BDSX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1439725 BDSX stock profile & AI dashboard →

13F Pro Quality Score

32.3/100

Rank #2,277 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

88.1/100

Profitability

11.8/100

Balance Sheet

4.0/100

Earnings Quality

30.0/100

Free Cash Flow

10.3/100

Institutional Flow

99.1/100

Revenue Scale

15.7/100

Dilution Risk

27.0/100

BDSX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIODESIX INC (BDSX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDSX at 32.3/100 on a 32-signal composite quality model, placing it at rank #2,277 of 2,879 stocks — the bottom half of the AI-ranked universe. BDSX scores in the top quartile across institutional flow (99.1), revenue growth (88.1). Areas of concern include balance sheet strength (4.0) and free cash flow (10.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BIODESIX INC reports quarterly revenue of $25.6M, net income of $-7.8M, an operating margin of -24.3%. Top institutional holders of BDSX by reported 13-F value include AIGH Capital Management, Telemark Asset Management,, abrdn plc, based on the most recent SEC filings. BDSX trades on the Nasdaq exchange and files with the SEC under CIK 1439725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDSX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIODESIX INC directly from SEC EDGAR. BIODESIX INC's 13F Pro composite quality score has ranged between 8 and 39 since 2021, currently 32.3 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about BIODESIX INC

Quirks, history, and lore behind BDSX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. commercial-stage diagnostics company · listed on Nasdaq · headquartered in Colorado · focused on a single disease area.
2
The Numbers
Annual revenues in the low tens of millions — a small-cap biotech-adjacent name — with a commercial team selling directly to oncologists and pulmonologists.
3
The History
Founded in the mid-2000s, the company spent years developing blood-based tests and eventually went public via a SPAC merger around 2020.
4
The Secret
Its entire business is built on blood-based proteomic testing — using proteins circulating in the blood to guide treatment decisions for lung cancer patients.
5
The Lore
Its flagship tests — including Nodify Lung — help doctors decide whether a suspicious lung nodule actually needs an invasive biopsy, potentially sparing patients a risky procedure.
6
The Giveaway
A lung diagnostics specialist trading as BDSX, its name is literally a mashup of biology and diagnostics — and yes, it rhymes with "bio thesis."

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$25.6M

Net Income

Q1 2026

$-7.8M

Free Cash Flow

Q1 2026

$-10.2M

Operating Margin

Q1 2026

-24.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+80.3% YoY

$88.5MFY 2025

FY20 $45.6MFY22 $38.2MFY23 $49.1MFY25 $88.5M

Net Income

+32.4% YoY

$-35.3MFY 2025

FY20 $-65.4MFY22 $-65.4MFY23 $-52.1MFY25 $-35.3M

Operating Income

+32.6% YoY

$-27.9MFY 2025

FY20 $-22.9MFY22 $-50.6MFY23 $-41.3MFY25 $-27.9M

EPS (Diluted)

-629.7% YoY

$-4.67FY 2025

FY20 —FY22 $-1.55FY23 $-0.64FY25 $-4.67

Total Assets

-11.7% YoY

$87.5MFY 2025

FY20 $121.1MFY22 $92.9MFY23 $99.1MFY25 $87.5M

Total Debt

+24.8% YoY

$50.0MFY 2025

FY20 $28.1MFY22 $30.1MFY23 $40.1MFY25 $50.0M

Op. Cash Flow

-1.8% YoY

$-23.3MFY 2025

FY20 $-21.4MFY22 $-45.0MFY23 $-22.9MFY25 $-23.3M

Metric	FY 2025	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$88.5M +80.3%	$49.1M +28.5%	$38.2M -16.1%	$45.6M +85.6%	$24.6M
Net Income	$-35.3M +32.4%	$-52.1M +20.3%	$-65.4M +0.0%	$-65.4M -113.0%	$-30.7M
Operating Income	$-27.9M +32.6%	$-41.3M +18.3%	$-50.6M -120.6%	$-22.9M +14.2%	$-26.7M
EPS (Diluted)	$-4.67 -629.7%	$-0.64 +58.7%	$-1.55	—	—
Total Assets	$87.5M -11.7%	$99.1M +6.7%	$92.9M -23.3%	$121.1M +190.8%	$41.6M
Total Debt	$50.0M +24.8%	$40.1M +33.0%	$30.1M +7.3%	$28.1M	—
Operating Cash Flow	$-23.3M -1.8%	$-22.9M +49.1%	$-45.0M -110.5%	$-21.4M +1.7%	$-21.7M

AI Insight: BDSX Financial Trends

BIODESIX achieved first positive operating cash flow of $1M in Q4 2025 despite persistent losses and equity erosion.

• Revenue grew from $18M in Q2 2024 to $26M in Q1 2026, with Q4 2025 hitting peak of $29M.

• Operating losses narrowed from $8M in Q2 2024 to $2M in Q4 2025 before widening to $6M in Q1 2026.

• Operating cash flow turned positive to $1M in Q4 2025 after eight quarters of negative cash generation.

• Total debt increased from $40M to $50M starting Q2 2025 while equity declined from $36M to $9M.

⚠ Equity turned negative in Q3 2025 at $-2M before recovering to $9M in Q1 2026.

⚠ Operating cash flow reversed from positive $1M in Q4 2025 to negative $10M in Q1 2026.

AI Insight: BDSX Ratio Trends

BDSX showed dramatic profitability improvement in Q4 2025 with operating margin reaching -6.8% from -50.9% lows, but deteriorated again in Q1 2026.

• Operating margin improved sharply from -50.9% in Q1 2025 to -6.8% in Q4 2025, the best level in the dataset.

• ROIC strengthened from -76.0% in Q2 2025 to -16.6% in Q4 2025, showing significant operational recovery.

• Operating margin deteriorated to -24.3% in Q1 2026 from Q4 2025's -6.8%, reversing the improvement trend.

⚠ Debt-to-equity ratio spiked dramatically from 1.92 in Q4 2024 to 43.95 in Q2 2025, indicating severe leverage stress.

⚠ Q1 2026 margin decline suggests Q4 2025 improvement may not be sustainable without further operational changes.

Get alerted when BDSX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIODESIX INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BDSX

AIGH Capital Management LLC
$11.0M758,328 sh
Telemark Asset Management, LLC
$7.1M489,824 sh
abrdn plc
$6.6M458,438 sh
Soleus Capital Management, L.P.
$6.0M416,599 sh
Birchview Capital, LP
$4.2M286,804 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.7M255,161 sh
Opaleye Management Inc.
$3.5M238,047 sh
MARSHALL WACE, LLP
$2.1M141,636 sh
ESSEX INVESTMENT MANAGEMENT CO LLC
$1.9M132,086 sh
StemPoint Capital LP
$1.0M70,004 sh

Fund	Value	Shares
AIGH Capital Management LLC	$11.0M	758,328
Telemark Asset Management, LLC	$7.1M	489,824
abrdn plc	$6.6M	458,438
Soleus Capital Management, L.P.	$6.0M	416,599
Birchview Capital, LP	$4.2M	286,804
VANGUARD CAPITAL MANAGEMENT LLC	$3.7M	255,161
Opaleye Management Inc.	$3.5M	238,047
MARSHALL WACE, LLP	$2.1M	141,636
ESSEX INVESTMENT MANAGEMENT CO LLC	$1.9M	132,086
StemPoint Capital LP	$1.0M	70,004

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BDSX on your watchlist

Track score changes the day BIODESIX INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BDSX a good stock to buy?

13F Pro's AI-powered analysis of BIODESIX INC (BDSX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BDSX are available on the BDSX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BDSX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BDSX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIODESIX INC's investment landscape.